# A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

> **NCT03328273** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 12 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ceralasertib
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT03328273
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-31
- **Primary completion:** 2021-09-07
- **Final completion:** 2026-08-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328273, "A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03328273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*